#USA #Indianapolis #Ulcerative Colitis #Eli Lilly #Mirikizumab

Lilly's Omvoh (Mirikizumab) Breakthrough Results in Pediatric Ulcerative Colitis

Eli Lilly and Company has made significant strides in the fight against pediatric ulcerative colitis with its medication, Omvoh (mirikizumab-mrkz). Recent results from the Phase 3 SHINE-2 study reveal that this treatment has not only met its primary clinical endpoints but has also established a new benchmark as the first IL-23p19 inhibitor to demonstrate one-year results in this specific patient population.

Significance of the Findings

The SHINE-2 study enrolled pediatric patients aged 6 to 17 who were suffering from moderately to severely active ulcerative colitis. The results showed that 81% of participants achieved clinical response after just 12 weeks of induction therapy. Impressively, 50% of these responders went on to attain clinical remission by the 52nd week, thus meeting the primary endpoint specified by the study. These results were recently presented during a late-breaking oral session at the United European Gastroenterology (UEG) Week 2026.

The secondary outcomes were equally promising: 71.2% of responding patients achieved symptomatic remission, while half of the responders maintained corticosteroid-free clinical remission without the need for surgical intervention. These findings underscore the potential of Omvoh to change the treatment landscape for children facing chronic gastrointestinal distress due to ulcerative colitis.

Clinical Context and Patient Need

Ulcerative colitis poses a profound challenge for pediatric patients, affecting an estimated 26,000 children and adolescents in the United States. Pediatric cases often present with more severe manifestations of the disease compared to adult-onset cases, leading to increased risks such as dependency on corticosteroids and potential surgical interventions. Notably, the SHINE-2 study included a population where over half of the patients had previously failed to respond to biologic therapies, highlighting the unmet medical need in this cohort.

Mark Genovese, M.D., Senior Vice President of Lilly Immunology Development, articulated the urgency of addressing these challenges: “For children and adolescents, the persistent bowel urgency and abdominal pain can disrupt their quality of life. The novel results from our study present a beacon of hope for those affected by this debilitating condition.”

Safety Profile and Ongoing Studies

Throughout the SHINE-2 study, the safety profile of Omvoh in the pediatric demographic appeared to align with that observed in adults, indicating that there were no new critical safety concerns. Most treatment-emergent adverse events reported were mild to moderate, and there were no serious adverse incidents directly associated with the therapy.

Lilly has long recognized the potential of mirikizumab in treating pediatric inflammatory bowel diseases, committing resources to both short-term and long-term studies. In addition to the ongoing follow-ups from SHINE-2, Lilly is also conducting studies evaluating combination therapies to enhance efficacy while ensuring the safety of young patients. The focus extends to understand how these treatments can not only provide relief but also restore quality of life through growth and development.

Future Outlook

Eli Lilly is preparing to submit the SHINE-2 findings to regulatory authorities across the globe to broaden the indication for Omvoh to include pediatric patients. If successful, this would mark a remarkable advancement in treatment options for ulcerative colitis, equipping healthcare providers with a new tool to manage this chronic illness effectively.

In summary, the promising results from the SHINE-2 study reflect a pivotal moment in the treatment of pediatric ulcerative colitis. By pushing forward with regulatory submissions, Lilly aims to address the substantial burden that this disease places on children and their families, paving the way for a healthier future.

• ---